Gelonghui July 14?Guangji Pharmaceutical (000952.SZ) announced that it expects the net profit attributable to shareholders of listed companies to be 22.5 million yuan to 29 million yuan in 2023, compared with 24.6962 million yuan in the same period last year, and 24.11 million yuan to 30.61 million yuan after deducting non-recurring profits and losses, compared with a profit of 13.0868 million yuan in the same period last year. Main reasons:
1. Affected by the intensification of market competition, the sales volume of the company's leading products with high content of vitamin B2 has decreased, and the sales income and net profit have declined.
2. During the reporting period, the expansion of marketing channels, the provision of compensation expenses in restricted stock incentive plans and the increase in the scale of interest-bearing liabilities led to an increase in expenses during the period compared with the same period last year.
3. The non-recurrent profit and loss during the reporting period was about 1.61 million yuan, a decrease of about 10 million yuan compared with the same period last year, mainly due to the decrease in non-recurrent profit and loss of joint venture units in terms of shareholding ratio compared with the same period last year.